Feb 14 |
We're Keeping An Eye On IRIDEX's (NASDAQ:IRIX) Cash Burn Rate
|
Feb 6 |
Iridex receives European patent on micropulse technology
|
Feb 6 |
Iridex Corporation Receives European Patent on MicroPulse Technology
|
Jan 24 |
Iridex Announces First Patient Enrollment in MicroPulse® TLT Clinical Study Conducted in Collaboration with Imperial College Healthcare NHS Trust
|
Jan 11 |
Iridex Launches New Iridex 532® and Iridex 577® Lasers in US Market Marking 35 Years of Laser Innovation in Treating Retina Disorders & Glaucoma
|
Dec 28 |
Iridex Confirms Medicare Administrative Contractors Retired Local Coverage Determinations that Restricted Cyclophotocoagulation
|
Nov 27 |
Iridex Corporation Announces Successful Appeal for Revision of Recent Medicare LCDs to Provide Broader Coverage of Cyclophotocoagulation
|
Nov 14 |
Iridex: Q3 Earnings Insights
|
Nov 14 |
IRIDEX GAAP EPS of -$0.11 beats by $0.02, revenue of $12.9M misses by $0.58M
|
Nov 14 |
Iridex Reports Third Quarter 2023 Financial Results and Business Update
|